Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Den forbedrede virkning af C-Kit (+) lever endotelceller med Mertk-mangel på ikke-alkoholisk steatohepatitis

16. november 2026 opdateret af: Shanghai East Hospital

The prevalence of non-alcoholic fatty liver disease (NAFLD) has been steadily increasing, with 10-20% of affected individuals progressing to non-alcoholic steatohepatitis (NASH). NASH is pathologically characterized by hepatic inflammation, steatosis, and hepatocyte injury. Furthermore, this condition carries a significant risk of progression to advanced hepatic fibrosis (pathological Scheuer fibrosis stage F≥3), cirrhosis, and even hepatocellular carcinoma (HCC). In recent years, NASH has emerged as the leading contributor to the growing burden of cirrhosis worldwide, representing a major public health challenge. Despite the high incidence and clinical severity of NAFLD, there are currently no FDA-approved therapeutic agents for its management. Therefore, elucidating the molecular mechanisms underlying NAFLD-associated NASH progression is critical for developing targeted pharmacological interventions capable of preventing, ameliorating, or potentially reversing disease progression.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

I. Study Background Non-alcoholic fatty liver disease (NAFLD) has become one of the most prevalent liver disorders globally. Despite its high incidence and severity, no effective therapeutic agents currently exist. Existing treatments focus on symptomatic relief, such as hepatoprotection and enzyme reduction, rather than addressing the underlying pathogenesis. Therefore, elucidating the mechanisms driving the progression of NAFLD-related non-alcoholic steatohepatitis (NASH) and hepatic fibrosis is critical for developing preventive, ameliorative, or even curative strategies, holding significant strategic importance.

  1. Role of LSECs in NAFLD Pathogenesis:

    Liver sinusoidal endothelial cells (LSECs), the primary components of the hepatic sinusoidal endothelium, form a physical barrier regulating substance exchange between the hepatic parenchyma and circulation. As highly specialized endothelial cells (ECs) and the most abundant non-parenchymal cells (NPCs) in the liver, LSECs play pivotal roles in hepatic pathophysiology. Targeting LSEC function represents a promising approach to mitigate NAFLD progression and complications.

  2. Heterogeneous Transcriptomic Features of LSEC Subpopulations in NAFLD:

    Single-cell RNA sequencing (scRNA-seq) enables genome-wide amplification and sequencing at the single-cell level. In the liver, hepatocytes (HCs) and NPCs exhibit marked transcriptomic heterogeneity, underpinning metabolic and functional zonation. This highlights the potential of single-cell analysis in understanding liver diseases. However, scRNA-seq studies on LSECs in NAFLD remain unexplored.

  3. Hypothesis: C-Kit(+)/Gas6(-)-LSEC Subpopulation Exacerbates NAFLD via Gas6/Mertk-Mediated Regulation of PINK1 Mitophagy:

Bone marrow-derived endothelial progenitor cells (EPCs), marked by C-Kit (CD117), may express C-Kit in ECs under pathological conditions. Gas6, a ligand for TAM receptors (Tyro3, Axl, Mertk), activates downstream signaling cascades regulating cell migration, inflammation, survival, and mitophagy. In NAFLD, Gas6/Mertk exhibits cell-specific roles : Anti-inflammatory in hepatic macrophages; Pro-fibrotic in hepatic stellate cells (HSCs); Protective in hepatocytes (HCs). However, the role of Gas6/Mertk in LSECs during NAFLD remains unknown. Mitochondrial dysfunction is a hallmark of NAFLD, and impaired mitophagy (e.g., PINK1 deficiency) exacerbates hepatic inflammation, steatosis, and fibrosis. Emerging evidence suggests Gas6/Mertk enhances mitophagy to preserve mitochondrial function. For instance, Mertk-/- mice exhibit cardiomyocyte mitochondrial dysfunction, and Gas6 promotes mitophagy.

Our preliminary scRNA-seq data from HFD/ND mice identified a unique C-Kit(+)/Gas6(-)-LSEC subpopulation. These LSECs induced mitophagy impairment in co-cultured HCs/HSCs, manifesting as mitochondrial senescence, oxidative stress, HSC activation, HC lipid deposition, and inflammation. Investigating how this subpopulation drives NAFLD progression will unveil novel pathophysiological mechanisms and therapeutic targets, forming the basis of this study.

II. Study Objectives To elucidate the expression levels of C-Kit and Gas6/Mertk ligand-receptor pairs in liver tissues of NAFLD patients.

III. Study Procedures

(1) Inclusion and Exclusion Criteria

  1. Inclusion Criteria: NAFLD diagnosis per Guidelines for the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease (2018 Edition). Age 18-65 years.
  2. Exclusion Criteria: Cirrhosis (compensated or decompensated), hepatocellular carcinoma, active viral hepatitis (HBV, HCV), primary biliary cholangitis, primary sclerosing cholangitis, recent history of illicit drug use, alcohol intake≥20 g/day for women and ≥30 g/day for men, current pregnancy or breastfeeding, severe comorbidities.

(2) Study Design

  1. Liver Biopsy and Tissue Collection:

    Ultrasound-guided liver biopsy in 6 NAFLD patients. Histopathological evaluation (HE, Masson staining) for NASH and fibrosis (NAS and Scheuer scoring). Clinical data collection and liver tissue storage (-80°C).

  2. Expression Analysis of C-Kit and Mertk:

Immunofluorescence co-staining of liver tissues. 3. Statistical Analysis: Compare C-Kit and Mertk expression levels in mild and severe NAFLD patients.

(3) Enrollment and Workflow

  1. Baseline Data Collection:

    ①Demographic and clinical parameters: name, sex, age, ethnicity, birthdate, height, weight, disease onset, contact information.

    ② Laboratory tests: CBC, ALT, AST, TBIL, TG, cholesterol, glucose, total protein, albumin.

    ③Clinical assessments: blood pressure, BMI, abdominal ultrasound, FibroScan.

  2. Biopsy Protocol:

    • Ultrasound-guided percutaneous liver biopsy within 1 month of enrollment. ②Tissue specimen requirements: ≥3 mm diameter, 5-8 mm length. ③Storage: -80°C for C-Kit and Mertk gene analysis.

IV. Expected Outcomes Clarify the regulatory relationship between C-Kit (+) LSECs and the Gas6-Mertk signaling pathway in NAFLD patient liver tissues.

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

6

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200120
        • Shanghai East Hospital (East Hospital Affiliated To Tongji University)

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Sandsynlighedsprøve

Studiebefolkning

The study population comprised adults with NAFLD confirmed by imaging (ultrasound, CT, or MRI), excluding secondary causes (e.g., alcohol consumption >30/20 g/day for men/women, viral hepatitis, or steatogenic medications). . Exclusion criteria included Cirrhosis (compensated or decompensated), hepatocellular carcinoma, primary biliary cholangitis, primary sclerosing cholangitis, recent history of illicit drug use, current pregnancy or breastfeeding, severe comorbidities. NAFLD severity was categorized using non-invasive fibrosis scores (NFS) or liver biopsy (steatosis, inflammation, fibrosis staging).

Beskrivelse

Inclusion Criteria:

  • Clinical diagnosis of Non-Alcoholic Fatty Liver Disease
  • Age 18-65 years

Exclusion Criteria:

  • Cirrhosis (compensated or decompensated)
  • Hepatocellular carcinoma
  • Active viral hepatitis (HBV, HCV)
  • Primary biliary cholangitis
  • Primary sclerosing cholangitis
  • Recent history of illicit drug use
  • Alcohol intake≥20 g/day for women and ≥30 g/day for men
  • Current pregnancy or breastfeeding
  • Severe comorbidities.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: CROSS_SECTIONAL

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Mertk expression levels of liver tissues
Tidsramme: From enrollment to the end of treatment at 4 weeks
  1. Liver Biopsy and Tissue Collection:

    Ultrasound-guided liver biopsy in 6 NAFLD patients. Histopathological evaluation (HE, Masson staining) for NASH and fibrosis (NAS and Scheuer scoring). Clinical data collection and liver tissue storage (-80°C).

  2. Expression Analysis of Mertk:

    Immunofluorescence staining of liver tissues.

  3. Statistical Analysis:

Compare Mertk expression levels between mild and severe NAFLD patients.

From enrollment to the end of treatment at 4 weeks
C-Kit expression levels of liver tissues
Tidsramme: From enrollment to the end of treatment at 4 weeks
  1. Liver Biopsy and Tissue Collection:

    Ultrasound-guided liver biopsy in 6 NAFLD patients. Histopathological evaluation (HE, Masson staining) for NASH and fibrosis (NAS and Scheuer scoring). Clinical data collection and liver tissue storage (-80°C).

  2. Expression Analysis of C-Kit:

    Immunofluorescence staining of liver tissues.

  3. Statistical Analysis:

Compare C-Kit expression levels between mild and severe NAFLD patients.

From enrollment to the end of treatment at 4 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. april 2024

Primær færdiggørelse (Faktiske)

31. oktober 2025

Studieafslutning (Faktiske)

31. oktober 2025

Datoer for studieregistrering

Først indsendt

30. marts 2025

Først indsendt, der opfyldte QC-kriterier

30. marts 2025

Først opslået (Faktiske)

6. april 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. november 2026

Sidst verificeret

1. marts 2025

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • Approval No.2024YS-050

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .